Navigation Links
Marburg virus disease in Angola - update

As of 29 March 2005, the Ministry of Health has reported a total of 124 cases and 117 deaths in Cabinda, Luanda and Uige. All these cases had originated in Uige Province. Ten of these cases have been laboratory confirmed by the Centers for Disease Control and Prevention (CDC), Atlanta, USA.

The team from WHO, including experts from the Inter-country programme for southern Africa, the Regional Office for Africa (AFRO) and from Headquarters, and partners in the Global Outbreak Alert and Response Network (GOARN) are supporting the Ministry of Health, Angola to strengthen active surveillance and contact tracing.

Médecins sans Frontières (Belgium, France, Holland and Spain) are assisting with infection control and establishing isolation facilities in Uige hospital. Experts from the Department of Infectious Diseases, Manchester, United Kingdom and Johannesburg Hospital, South Africa are providing assistance in infection control in Luanda, where training will be provided for health care staff from all provinces in the country. The Canadian National Microbiology Laboratory will be setting up a mobile laboratory in Uige and CDC will be providing laboratory support in Luanda. UNICEF is carrying out social mobilization activities, raising awareness of the disease in the community and also providing additional logistic support and equipment.

Two travelers returning to Portugal from Angola were investigated for possible Marburg virus infection and laboratory results were negative in tests performed by the Bernard-Nocht Institute for Tropical Medicine, Hamburg, Germany, a WHO Reference Laboratory.


'"/>

Source:WHO


Page: 1

Related biology news :

1. Marburg haemorrhagic fever in Angola update
2. WHO suspends Marburg work, appeals for new funds
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease
5. Association of herpesvirus with lung disorder questioned
6. Topical treatment shown to inhibit HIV and herpes simplex virus infection
7. Elusive HIV shape change revealed; Key clue to how virus infects cells
8. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
9. Live Recombinant Adenovirus Vaccine Technique Explored
10. Studies reveal methods viruses use to sidestep immune system
11. Norovirus, AIDS vaccine and Hepatitis Virus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: